Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

J Antimicrob Chemother. 2001 May;47(5):655-8. doi: 10.1093/jac/47.5.655.

Abstract

Ciprofloxacin-susceptible (n = 7) and -resistant (MIC >or=4 mg/L) (n = 15) clinical isolates of Streptococcus pneumoniae from diverse sources in Hong Kong were studied for target site modifications and efflux phenotype. Reserpine-inhibited efflux of ciprofloxacin and/or levofloxacin was common in both susceptible and non-susceptible isolates. The ParC substitutions K137N and/or S79F or Y were associated with increased ciprofloxacin MICS. The GyrA substitution S81F was only found in isolates with full resistance to ciprofloxacin (MIC >or=16 mg/L) and levofloxacin (MIC >or=8 mg/L). Among clinical isolates of S. pneumoniae, accumulation of target site mutations in strains with an efflux mechanism was associated with increasing MICs of fluoroquinolones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Infective Agents / pharmacology*
  • Bacterial Proteins / genetics*
  • Biological Transport
  • Drug Resistance, Microbial / genetics
  • Drug Resistance, Microbial / physiology
  • Fluoroquinolones
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Phenotype
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / metabolism

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • Fluoroquinolones